Recent Reports


2010-01-25: Medical Research, Diagnostic Substances, Life Science Tools Report
7 leading Analysts; and top management from 2 Sector Firms examine this vital industry in this 38 page report from The Wall Street Transcript.
More Information
Order this Report

2009-12-07: Consumer Health Services Report
7 leading Analysts; and top management from 2 Sector Firm examine this vital industry in this 53 page report from The Wall Street Transcript.
More Information
Order this Report

2009-11-02: Pharmaceuticals Report
3 leading Analysts; and top management from 16 Sector Firms examine this vital industry in this 76 page report from The Wall Street Transcript.
More Information
Order this Report

2009-10-19: Biotechnology Report
3 leading Analysts; 2 Money Managers; and top management from 12 Sector Firms examine this vital industry in this 70 page report from The Wall Street Transcript.
More Information
Order this Report

09.21.09: Medical Real Estate: Healthcare REITs, Long-Term Care Facilities & Hospitals Report
3 analysts and 6 sector firms examine the medical real estate segment in this 45 page report from The Wall Street Transcript.
More Information
Order this Report

09.21.09: Medical Devices Report
4 analysts and 7 sector firms examine the medical devices segment in this 41 page report from The Wall Street Transcript.
More Information
Order this Report

09.14.09: Medical Research Services Report
2 analysts, and 4 sector firms examine the medical research services segment in this 23 page report from The Wall Street Transcript.
More Information
Order this Report

Search TWST Online

TWST Newsletter

Give us your email address and receive the TWST Newsletter.


Analyst Interview Excerpt
Outlook for Large-Cap Biotechnology - Maged Shenouda - UBS Investment Research


Full article published: 10/19/2009


For Subscribers

Get this article online now!

Order just this article
TWST: What do you cover within the biotech sector?
Mr. Shenouda: I cover U.S. large-cap biotechnology as well as some mid- and small-cap names.

TWST: How do you define biotech?
Mr. Shenouda: The demarcation is getting grayer and grayer between these companies. Initially, it was companies that manufactured or developed protein therapeutics, but now you see that biotech companies are getting involved in small molecules, and small molecules were historically the domain of pharmaceutical companies as well as specialty pharma companies. Again, the demarcation is getting a lot vaguer. Now largely biotech companies, Amgen aside, Gilead aside too, are smaller than pharma companies and their growth trajectories are a bit higher. More specifically, their revenue and EPS growth trajectories are a bit higher.

TWST: So you believe we're going to have more and more overlap between these companies?
Mr. Shenouda: Exactly. In the biotech universe you have a lot of overlap in terms of the large caps. Now with small caps, these are development-stage organizations, largely without products on the market in various stages from preclinical to Phase III development. Some of them do have products on the market, but most don't. And the investment opportunity on the upside lies in development progress and hopefully one day getting one of these products to cross the line into commercialization.

 

Tickers included in this excerpt: AMGN, BIIB, CELG, ESALY, GILD, HGSI, TKPHF

 

For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.